RE:DelayMutt67 - You should just be honest and change your name to Troll, you troll.
There is NO evidence they will consolidate shares. MANY companies vote for an RS every single year at the AGM just so it's in their arsenal if things get to that point without the necessity of holding a special meeting. It's a srandard practice and most RS options are never executed. This one will most likely expire nad be re-newed at the next AGM. In fact, your FUD-spouting point about the dose ranging trial being minimally delayed (welcome to pharma, scrub) DECREASES the likelihood of them consolidating shares by 5/2019.
RS are performed when a company is 1.) trying to stay listed on their current exchange, 2.) trying to uplist to another exchange, or 3.) trying to woo financiers who require the SP to be higher and share count to be lower. Antibe is in absolutely NO danger of delisting from the Venture and they have stated they already have the $3 Million for the dose-ranging trial, so they would only RS when anticipating an uplisting to TSX or Nasdaq, which won't happen for some time.
It's obvious you're just trying to bash to shake a few weak shares from the trees...
Good luck, chump.
Mott67 wrote: Bottom line here for investors is that there is a delay in trial startup and results now will be second quarter 2019.
That means next major catalyst for stock price could be nearly a year from now. Most people will bail now and come back in later at a lower price (imho ).
Also reverse red split issue hanging overhead till then, will also add downward pressure.
In the end I believe this stock will be a winner long term, but for now there is not much reason to tie up $$.